ENTRADA THERAPEUTICS INC
TRDANASDAQTrading Snapshot
- Day Range
- $4.35 – $5.03
- 52-Week Range
- $4.11 – $16.45
- Volume (shares)
- 479,051
- Avg Volume (shares)
- —
- Shares Outstanding
- 38.9M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $25M
- Last Q Revenue
- $898,000
- P/E Ratio
- -1.1
- P/S Ratio
- 36.6x
- EPS (TTM)
- $-3.93
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −3.9%
ENTRADA THERAPEUTICS INC
TRDA
StockOtter · stockotter.spaceAbout ENTRADA THERAPEUTICS INC
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR)
Entrada Therapeutics (NASDAQ: TRDA - Get Free Report) and X4 Pharmaceuticals (NASDAQ: XFOR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two busine
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. “Linea has a proven track record of scaling organizations and d
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entr
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate expos
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from $5.61, driven by potential validation of its EEV platform. ENTR-601-44's initial dystrophin increase was disappointing, but lower pedia
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE)